Amikacin Pharmacokinetics in Pediatric Patients with Burn Injuries Compared to Those with Oncology Conditions

Xiaoxi Liu, Anne Smits, Tian Yu, Stephanie Wead, Alice Neely, Richard J. Kagan, Daniel P. Healy, Karel Allegaert, Catherine M.T. Sherwin

Research output: Contribution to journalArticlepeer-review

Abstract

Physiologic changes due to disease status can lead to highly variable pharmacokinetics (PK) of amikacin in children. Therefore, considerations should be given when determining optimal amikacin does for patients with a specific diseases. Improved understanding of factors influencing PD can allow for the optimizing of dosage regimens to reduce adverse effects.

The aim of the study was to undertake a comparative pharmacometic analysis of amikacin use in pediatric patients with burn injuries verses those with oncology conditions.

Original languageAmerican English
JournalDefault journal
StatePublished - Jan 1 2016

Disciplines

  • Medical Specialties
  • Medicine and Health Sciences
  • Pediatrics

Cite this